Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest LaboratoriesNSE:QUESTLAB -2.36%45 EV-to-Revenue is 1.21 as of Aug. 21, 2026, which is 23% below its 10-year median of 1.57. GuruFocus rates NSE:QUESTLAB with a GF Score™ of 45/100. The stock has 5 warning signs investors should review. Among 961 Drug Manufacturers companies, Quest Laboratories ranks better than 73.67% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Quest Laboratories's enterprise value is ₹1,354 Mil.
Quest Laboratories's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,118 Mil. Therefore, Quest Laboratories's EV-to-Revenue for today is 1.21.
The historical rank and industry rank for Quest Laboratories's EV-to-Revenue or its related term are showing as below:
NSE:QUESTLAB'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.14 Med: 1.57 Max: 3.13
Current: 1.2
During the past 6 years, the highest EV-to-Revenue of Quest Laboratories was 3.13. The lowest was 1.14. And the median was 1.57.
NSE:QUESTLAB's EV-to-Revenue is ranked better than 73.67% of 961
companies
in the Drug Manufacturers industry
Industry Median: 2.47
vs NSE:QUESTLAB: 1.20
Quest Laboratories's share price for today is ₹85.85.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Mar. 2026 was ₹68.19.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Laboratories EV-to-Revenue Related Terms
Quest Laboratories EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for Quest Laboratories's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:QUESTLAB vs LLY, JNJ, ABBV: EV-to-Revenue Comparison
For the Drug Manufacturers - General subindustry, Quest Laboratories's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Laboratories EV-to-Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Quest Laboratories's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Quest Laboratories's EV-to-Revenue falls into.
Quest Laboratories's current Enterprise Value is ₹1,354 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Quest Laboratories's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,118 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Laboratories (NSE:QUESTLAB) has a EV-to-Revenue of 1.21 as of Aug. 21, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Quest Laboratories and its competitors. This is 23% below median its historical median of 1.57. Over the past decade, Quest Laboratories' EV-to-Revenue has ranged from 1.14 to 3.13. According to the industry distribution chart, Quest Laboratories ranks #253 out of 961 companies in the Drug Manufacturers industry, placing it in the top 26.3%.
Is Quest Laboratories' EV-to-Revenue too high?
Quest Laboratories' current EV-to-Revenue of 1.21 is 23% below median its 10-year median of 1.57. Over the past 10 years, this metric has ranged from a low of 1.14 to a high of 3.13. The Drug Manufacturers industry median EV-to-Revenue is 2.47. Quest Laboratories' value of 1.21 is 51% below this industry median. Based on the distribution chart, Quest Laboratories ranks #253 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Quest Laboratories has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Quest Laboratories' EV-to-Revenue compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Quest Laboratories ranks #253 out of 961 companies for EV-to-Revenue. This puts Quest Laboratories in the upper half of its industry. The industry median EV-to-Revenue is 2.47. Quest Laboratories' value of 1.21 is 51% below this benchmark. Historically, Quest Laboratories' own EV-to-Revenue has ranged from 1.14 to 3.13 over the past decade. While the company's 10-year median is 1.57 vs. the industry median of 2.47, Quest Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Drug Manufacturers company?
The median EV-to-Revenue among Drug Manufacturers companies is 2.47, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Laboratories's current EV-to-Revenue of 1.21 is 51% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Quest Laboratories and its competitors. For the Drug Manufacturers industry, the median EV-to-Revenue is 2.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Laboratories's current EV-to-Revenue is 1.21, which is 23% below median its own 10-year median of 1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Laboratories stock overvalued right now?
Quest Laboratories (NSE:QUESTLAB) has a current EV-to-Revenue of 1.21. The current EV-to-Revenue is 1.21, which is 23% below median its 10-year median of 1.57 and 51% below the Drug Manufacturers industry median of 2.47. Quest Laboratories' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For Quest Laboratories (NSE:QUESTLAB), the current EV-to-Revenue is 1.21 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quest Laboratories Ltd is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces various products, comprising ethical drugs, generic drugs, and over-the-counter drugs, and is also available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids, among others. The company operates in a single segment of Drugs and Chemicals.
45GF Score
Get the complete analysis for NSE:QUESTLAB
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QUESTLAB has been successfully added to your 
